Sort By

  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

Will Taiwan tension derail emerging market allocations?

As investors start to look past the pandemic, the economic cost and scarring from Covid-19 has been significant. The International Monetary Fund (IMF) says “unlike the 2008 crisis, emerging markets and developing economies are expected to suffer more scarring than advanced economies”. In the same way that the US and Australia were able to provide…
Ishan Dan | 17th May 2021 | More
Thinking forward – ASX MedTech leaders

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
James Dunn | 7th Oct 2020 | More